PMGC Holdings Inc.

PMGC Holdings Inc. has entered into two new agreements to enhance its investor relations and marketing efforts. The company signed a Consulting Agreement with IR Agency LLC for $300,000 and a Digital Marketing Services Agreement with Senergy Communications Capital Inc. for C$185,000. Additionally, its subsidiary NorthStrive Biosciences announced preliminary results from a preclinical study of its EL-32 candidate in combination with Semaglutide, indicating potential lean-mass preservation findings and informing the strategy for a planned follow-on study in Q1 2027.

PMGC Holdings Inc. has entered into a Subscription Agreement to purchase US$1,845,000 in secured debentures of Nuclea Energy Canada Inc. These debentures are part of a larger offering by Nuclea Canada to fund its acquisition of assets from Moltex Energy Limited. The debentures are non-interest bearing and have a short maturity period, with repayment contingent on the successful completion of the acquisition. PMGC Holdings Inc. will also receive a finance fee of US$45,000 for its participation.

PMGC Holdings Inc. announced its compliance with Nasdaq's newly approved Market Value of Listed Securities (MVLS) continued-listing requirement. The company is also actively working with market-data providers to correct inaccurate share count and market capitalization data, confirming 8,095,835 shares of common stock issued and outstanding as of July 29, 2026. Additionally, PMGC highlighted its financial position for Q1 2026, reporting total assets of approximately $26.0 million and revenue of approximately $682,000, which surpassed its full-year 2025 revenue.

PMGC Holdings Inc. announced that its wholly owned subsidiary, A&B Aerospace, Inc., has entered into a two-year Long-Term Agreement with Precision Aerospace & Defense Group, Inc. to manufacture and supply precision-machined aerospace and defense components. The agreement, which automatically renews, positions A&B Aerospace to support U.S. federal government prime contracts. Separately, PMGC Capital LLC, another subsidiary, made a $500,000 strategic equity investment in PAD Group's Series F Convertible Preferred Stock, aligning the long-term interests of both companies.

PMGC Holdings Inc.'s wholly-owned subsidiary, NorthStrive Defense Tech LLC, announced a project services agreement with Deploy360. This agreement is for the independent validation and testing of a patented GPS-denied autonomous navigation technology, for which NorthStrive Defense Tech holds an exclusive option to license. The project, utilizing Deploy360's D360-Sentinel AI™ platform, aims to provide a technical assessment of the technology's software and performance under simulated conditions, with a final report due by October 2026. This validation is a crucial step in NorthStrive Defense Tech's evaluation process before potentially pursuing a definitive license agreement.

PMGC Holdings Inc.'s subsidiary, NorthStrive Biosciences, announced plans to initiate an independent flow cytometry (FACS) analysis program for its engineered probiotic therapeutic candidate, EL-22. The study aims to quantify latent myostatin antigen expression on NorthStrive-manufactured Lactobacillus casei and establish comparability against previously manufactured material. This work is intended to strengthen EL-22's product identity and manufacturing consistency, supporting its development to preserve muscle during weight loss, including with GLP-1 receptor agonists.

PMGC Holdings Inc. announced that its wholly-owned subsidiary, AGA Precision Systems LLC, has entered into a Merger Agreement with another wholly-owned subsidiary, A&B Aerospace, Inc. Under the agreement, AGA will merge into A&B, with A&B Aerospace, Inc. continuing as the surviving entity. The merger involves the cancellation of AGA's membership interests without consideration, while A&B's shares will remain unaffected, with an anticipated effective date of July 2, 2026.

PMGC Holdings Inc.'s wholly owned subsidiary, NorthStrive Defense Tech LLC, has entered into a Standard Exclusive License Agreement with a licensor. This agreement grants NorthStrive Defense Tech a worldwide, non-transferable, exclusive license to develop and commercialize products covered by U.S. Patent No. 12,291,334 and associated know-how in the aerospace and defense fields. The subsidiary will pay a license issue fee, annual maintenance fees, and royalties, and is committed to a development plan with diligence milestones.

PMGC Holdings Inc. announced the merger of its two precision manufacturing portfolio companies, AGA Precision Systems LLC and A&B Aerospace, Inc. A&B Aerospace will be the surviving entity, consolidating the businesses under one corporate structure. This strategic move is expected to streamline operations, share resources, and strengthen PMGC's aerospace manufacturing platform, while both existing sites continue to operate.

PMGC Holdings Inc.'s subsidiary, NorthStrive Biosciences Inc., announced positive results from Phase III of its AI-driven drug discovery program with Yuva Biosciences. The program, utilizing Yuva's MitoNova™ AI platform, identified four small-molecule candidates (C1, C2, C3, C4) that significantly increased ANT1 protein expression in primary human skeletal muscle cells. The strongest candidates demonstrated dose-dependent induction, with increases up to +50%. These findings support advancing the compounds for further confirmatory testing and development, focusing on muscle preservation and metabolic stress.